Oxy Patents (Class 562/444)
-
Patent number: 6255285Abstract: The present invention has as its object providing phenethylamine derivatives that typically function as a motilin receptor antagonist and which are useful as medicines. The invention provides compounds represented by the general formula (1): (wherein A is typically an amino acid residue, R1 is typically R6—CO—, R2 is typically a hydrogen atom, R3 is typically —CO—R7, R4 is typically an alkyl group, R5 is typically a hydroxyl group, R6 is typically an alkyl group, and R7 is typically an amino group).Type: GrantFiled: February 15, 2000Date of Patent: July 3, 2001Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Ken-ichiro Kotake, Toshiro Kozono, Tsutomu Sato, Hisanori Takanashi
-
Patent number: 6232467Abstract: Amines and amino acids are prepared by reacting an amine, a carbonyl derivative, and an organoboron compound under mild conditions.Type: GrantFiled: June 27, 1997Date of Patent: May 15, 2001Assignee: University of Southern CaliforniaInventors: Nicos A. Petasis, Ilia A. Zavialov
-
Patent number: 6225351Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, AA and Y are as defined herein, inhibit phosphodiesterase type IV or inhibit the production of tumor necrosis factor, and therefore are useful in the treatment of certain conditions and diseases including asthma, arthritis, and sepsis.Type: GrantFiled: July 6, 1998Date of Patent: May 1, 2001Assignee: Pfizer Inc.Inventor: Edward F. Kleinman
-
Patent number: 6218572Abstract: A process for preparing N-protected N-alkylated amino acids of the formula I: in which the substituents have the meanings stated in the description, comprises mixing a compound of the formula II with a solution of potassium tert-butanolate in a non-protic organic solvent, and subsequently adding a C1-2-alkyl halide.Type: GrantFiled: November 19, 1996Date of Patent: April 17, 2001Assignee: BASF AktiengesellschaftInventors: Ulrich Karl, Stefan Müller, Bernd de Potzolli
-
Patent number: 6197998Abstract: Provided is a process for efficiently producing N-glycyltyrosine of high purity represented by the following formula: a salt thereof, or a solvate thereof, which comprises adding dropwise to an aqueous suspension of tyrosine or a salt thereof 2 equivalents or more of a haloacetyl halide and an aqueous solution of an inorganic base simultaneously in the presence or absence of an organic solvent, and subjecting the resulting N-haloacetyltyrosine to a reaction with an ammonium ion. Also provided are N-glycyl-L-tyrosine dehydrate having the crystal structures showing specific diffraction patterns in X-ray powder diffraction and processes for producing the same which are characterized by comprising crystallizing the dihydrate from an ethanol-water mixed solvent or water.Type: GrantFiled: April 12, 1999Date of Patent: March 6, 2001Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Takashi Mimura, Eiichiro Imai, Takahiro Imai, Takehiro Ogasa, Masaji Kasai
-
Patent number: 6174887Abstract: An amide compound of the formula (I): wherein R is amino and the like, A is alkylene and the like, X is O, S and the like, M is arylene and the like, R1, R2, R3 and R4 are H, hydroxy and the like, R5 is H, alkyl and the like, m is an integer of 0-6, R6 is an optionally substituted aryl and the like, and R7 is H, an optionally substituted alkyl and the like, a pharmaceutically acceptable acid addition salt thereof and a pharmaceutical containing same as an active ingredient. The amide compounds exhibit superior suppressive effects on cytokines directly or indirectly involved in inflammations, such as IL-8, IL-1, IL-6, TNF-&agr;, GM-CSF and the like, and are useful for the prophylaxis and treatment of rheumatic diseases, arthritis due to gout and the like.Type: GrantFiled: February 20, 1998Date of Patent: January 16, 2001Assignee: Japan Tobacco Inc.Inventors: Junichi Haruta, Kazuhiko Sakuma, Yoshihiro Watanabe
-
Patent number: 6172058Abstract: A pharmaceutical compound of the formula in which R1 is C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-10 alkyl, C3-10 cycloalkyl-C2-10 alkenyl, C3-10 cycloalky-C2-10 alkynyl, optionally substituted phenyl-C1-10 alkyl, optionally substituted phenyl-C2-10 alkenyl, optionally substituted phenyl-C2-10 alkynyl, optionally substituted naphthyl, optionally substituted naphthyl-C1-10 alkyl, C1-10 alkoxy-C1-10 alkyl, C3-10 cycloalkoxy-C1-10 alkyl, optionally substituted heterocyclyl, optionally substituted heterocyclyl-C1-10 alkyl, optionally substituted phenyl fused to C5-10 cycloalkyl, optionally substituted tricyclic, optionally substituted tricyclic-C1-10 alkyl, or [optionally substituted phenyl(CH2)n]2-C1-10 alkyl, where n is 0 or 1 to 4, and R2 is hydrogen or one of the values for R1; or a salt or ester thereof.Type: GrantFiled: April 3, 1998Date of Patent: January 9, 2001Assignee: Lilly, SAInventors: Concepci{acute over (o)}n Pedregal Tercero, Ivan Collado Cano, Angel Maz{acute over (o)}n Ruiz
-
Patent number: 6153650Abstract: Novel gamma aminobutyric acids of formula (I) are disclosed and are useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, inflammation, and gastrointestinal damage. Processes for the preparation and intermediates useful in the preparation are also disclosed.Type: GrantFiled: March 1, 1999Date of Patent: November 28, 2000Assignee: Warner-Lambert CompanyInventors: Justin Stephen Bryans, David Christopher Horwell, Clare Octavia Kneen, Andrew John Thorpe, David Juergen Wustrow
-
Patent number: 6153591Abstract: The present invention is directed to novel dipeptides represented by the general Formula I: ##STR1## where R.sub.1 -R.sub.2 and AA are defined herein. The present invention relates to the discovery that compounds having Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire organs occurs.Type: GrantFiled: March 16, 1999Date of Patent: November 28, 2000Assignee: Cytovia, Inc.Inventors: Sui Xiong Cai, John Drewe, Yan Wang, Eckard Weber
-
Patent number: 6147113Abstract: The present invention provides blockers for glutamate transporters. During a series of syntheses searching for glutamate uptake inhibition in Xenopus oocytes injected with bovine glutamate transporter genes (BGLAST), we obtained .beta.-hydroxyaspartic acid derivatives of the following chemical formula (1): ##STR1## wherein R represents an aromatic acyl group which may be substituted on the ring, a straight or branched lower aliphatic acyl group, an aryl group which may be substituted on the ring, an aralkyl group which may be substituted on the ring, or a straight or branched lower alkyl group; and salts thereof. These compounds are blockers of glutamate transporters, which are useful for the understanding of the function of glutamate transporters and show promise for the treatment of various neurodegenerative diseases.Type: GrantFiled: October 24, 1997Date of Patent: November 14, 2000Assignee: Suntory LimitedInventors: Keiko Shimamoto, Yoshimi Yasuda, Masahiro Sakaitani, Bruno Lebrun
-
Patent number: 6100423Abstract: The present invention is directed to compounds of the formula ##STR1## where R.sup.1 is BOC or H, R is H or lower alkyl; X and Y are the same or different halo atoms selected from the group consisting of Cl, Br or I and pharmaceutically acceptable salts and isomers thereof.Type: GrantFiled: March 3, 1999Date of Patent: August 8, 2000Assignee: G. D. Searle & Co.Inventors: Joe T. Collins, Balekudru Devadas, Hwang-fun Lu, James W. Malecha, Julie Marion Miyashiro, Srinivasan Nagarajan, Joseph Gerace Rico, Thomas E. Rogers
-
Patent number: 6087530Abstract: An object of the present invention is to provide a process for producing a .beta.-amino-.alpha.-hydroxy acid derivative via efficient and industrially utilizable steps.The present invention provides a process for producing a .beta.-amino-.alpha.-hydroxy acid derivative represented by the general formula (2) given below which comprises hydrolyzing an .alpha.-amino-.alpha.', .alpha.-dihaloketone derivative of the general formula (1) given below in the presence of a base, followed by protecting the amino group or without protecting the same.Type: GrantFiled: November 15, 1999Date of Patent: July 11, 2000Assignee: Kaneka CorporationInventors: Shingo Matsumoto, Kazuhiko Matsuo, Tadashi Sugawa, Tadashi Moroshima, Kenji Inoue
-
Patent number: 6071510Abstract: The present invention provides modified amino acids for delivering active agents, and particularly biologically or chemically active agents. The preferred modified amino acids of the present invention include N-acylated or sulfonated amino acids. These modified amino acids are used as carriers to facilitate the delivery of a cargo to a target. Such modified amino acids are well suited to form non-covalent mixtures with biologically-active agents for oral administration to animals. Methods for the preparation and administration of the modified amino acids and compositions including the same are also provided.Type: GrantFiled: April 23, 1997Date of Patent: June 6, 2000Assignee: Emisphere Technologies, Inc.Inventors: Andrea Leone-Bay, Koc-Kan Ho, Jeffery Bruce Press, Nai-Fang Wang
-
Patent number: 6063955Abstract: A method for producing an optically active erythro-3-amino-2-hydroxybutyric ester as an important intermediate of pharmaceutical agents, specifically HIV protease inhibitor, in high purity and in high yield. The method includes producing an optically active erythro-3-amino-2-hydroxybutyric ester by oxidizing the hydroxyl group at the 2-position of an optically active 3-amino-2-hydroxybutyric ester, optically active at the 3-position, as represented by formula (I): ##STR1## (wherein R.sup.1 represents a phenyl group or a cyclohexyl group; R.sup.2 represents a protective group and R.sup.3 represents an unsubstituted or substituted alkyl residue; the steric configuration of *1 represents S configuration or R configuration), and then reducing erythro-selectively the resulting product by using aluminum alkoxide.Type: GrantFiled: February 3, 1999Date of Patent: May 16, 2000Assignee: Nippon Kayaku Kabushiki KaishaInventors: Hisao Satoh, Kenichi Yamamoto
-
Patent number: 6046235Abstract: A sulfur-containing amino acid compound having a high inhibitory activity on LTA.sub.4 hydrolase which is represented by the following formula: ##STR1## wherein R.sup.1 represents H, alkyl, optionally substituted phenyl alkyl, alkanoyl or optionally substituted benzoyl; R.sup.2 represents ester, amide or carboxyl; R.sup.3 represents hydroxyl, alkyl, halogenoalkyl, alkoxy, halogenoalkoxy, alkylthio, optionally substituted phenyl, optionally substituted phenoxy, optionally substituted phenylthio, halogen atom, alkylsulfonyl, halogenoalkylsulfonyl, nitro or cyano; R.sup.4 represents alkyl; A.sup.1 represents alkylene; and A.sup.2 represents alkylene.Type: GrantFiled: March 1, 1999Date of Patent: April 4, 2000Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Masato Horiuchi, Kenichi Fujimura, Hiroshi Suhara
-
Patent number: 6034266Abstract: The present invention refers to novel gem-difluoro compounds of formula: ##STR1## wherein: R.sub.1 can be hydrogen, acyl or acyl substituted; R.sub.2 is hydrogen, lower alkyl, lower alkyl substituted, nitro, halogen, methylenedioxy, trifluoromethyl or OR';Y is oxygen, sulfur or NR";R.sub.3 is hydrogen, lower alkyl, lower alkyl substituted, phenyl, aryl group substituted or metal selected of the group consisting of sodium, potassium, clcium, magnesium, zinc or aluminum;R' and R" are hydrogen, lower alkyl, lower alkyl substituted, phenyl or aryl substituted; and(a) in the group C.sub.1 -C.sub.Type: GrantFiled: September 17, 1996Date of Patent: March 7, 2000Assignee: Fundacao Oswaldo Cruz-FiocruzInventors: Nubia Boechat, Angelo Da Cunha Pinto
-
Patent number: 6020518Abstract: An object of the present invention is to provide a process for producing a .beta.-amino-.alpha.-hydroxy acid derivative via efficient and industrially utilizable steps.The present invention provides a process for producing a .beta.-amino-.alpha.-hydroxy acid derivative represented by the general formula (2) given below which comprises hydrolyzing an .alpha.-amino-.alpha.', .alpha.'-dihaloketone derivative of the general formula (1) given below in the presence of a base, followed by protecting the amino group or without protecting the same.Type: GrantFiled: May 14, 1999Date of Patent: February 1, 2000Assignee: Kaneka CorporationInventors: Shingo Matsumoto, Kazuhiko Matsuo, Tadashi Sugawa, Tadashi Moroshima, Kenji Inoue
-
Patent number: 6017925Abstract: This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are .alpha.v.beta.3 antagonists, .alpha.v.beta.5 antagonists or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.Type: GrantFiled: January 13, 1998Date of Patent: January 25, 2000Assignee: Merck & Co., Inc.Inventor: Mark E. Duggan
-
Patent number: 6018050Abstract: The invention relates to a new process for the preparation of optically active amino acids and amino acid derivatives of the general formula (I), wherein *, X and R.sup.1 to R.sup.4 have the meaning given in the description. Starting from commercially obtainable (-)-menthol or (+)-menthol, the enantiomerically pure compounds of the formula (I) are obtained in high yields. The method is particularly suitable for the preparation of sterically demanding amino acids and amino acid derivatives.Type: GrantFiled: April 30, 1998Date of Patent: January 25, 2000Assignee: Degussa AktiengesellschaftInventors: Hans-Josef Altenbach, Matthias Kottenhahn, Annegret Vogt, Mike Matthaus, Andreas Grundler, Michael Hahn
-
Patent number: 5990341Abstract: A process for the synthesis of hydroxyethylene dipeptide isosteres from .alpha.-N,N-di(protected)amino(alkyl or substituted alkyl) methyl ketones that can be efficiently carried out on an industrial scale. The process proceeds with excellent diastereoselectivity and chemical efficiency, and can be used to prepare a wide variety of hydroxyethylene dipeptide isosteres for a variety of uses, including as HIV-1 protease inhibitors and renin inhibitors.Type: GrantFiled: December 24, 1996Date of Patent: November 23, 1999Assignee: Emory UniversityInventors: Dennis C. Liotta, Bharat Ramkrishna Lagu
-
Patent number: 5990166Abstract: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.Type: GrantFiled: February 7, 1997Date of Patent: November 23, 1999Assignee: Emisphere Technologies, Inc.Inventors: Andrea Leone-Bay, Eric Wang, Donald J. Sarubbi, Harry Leipold
-
Patent number: 5985911Abstract: C-terminal compounds of formula ##STR1## are potent inhibitors of matrix metalloproteinase and are useful in the treatment of diseases in which matrix metalloproteinase play a role. Also disclosed are matrix metalloproteinase inhibiting compositions and a method of inhibiting matrix metalloproteinase in a mammal.Type: GrantFiled: December 17, 1997Date of Patent: November 16, 1999Assignee: Abbott LaboratoriesInventors: Steven K. Davidsen, Alan S. Florjancic, George S. Sheppard, Jamie R. Giesler, Lianhong Xu, Yan Guo, Michael L. Curtin, Michael R. Michaelides, Carol K. Wada, James H. Holms
-
Patent number: 5981573Abstract: A compound represented by general formula (I) or a pharmaceutically acceptable salt or ester thereof: [wherein each of Ar.sup.1, Ar.sup.2, Ar.sup.3 and Ar.sup.4 is an aryl group or an aromatic heterocyclic group; A.sup.1 is a C.sub.2-6 chain hydrocarbon group or a group represented by --A.sup.1a --W.sup.1 --A.sup.1b -- (wherein W.sup.1 is an oxygen atom, a sulfur atom, an ethynylene group, a cyclopropylene group or a group represented by --NR.sup.W --; A.sup.2 is a C.sub.2-8 chain hydrocarbon group; each of X and Y is an oxygen atom, a sulfur atom, a carbonyl group or a group represented by --CHR.sup.a -- or by --NR.sup.b --, or X and Y together represent a vinylene group or an ethynylene group; each of R.sup.1, R.sup.2, R.sup.3, R.sup.7 and R.sup.8 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group, a lower alkenyl group or a lower alkoxy group; each of R.sup.4 and R.sup.Type: GrantFiled: August 4, 1998Date of Patent: November 9, 1999Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Yoshikazu Iwasawa, Tetsuya Aoyama, Kumiko Kawakami, Sachie Arai, Toshihiko Satoh, Yoshiaki Monden
-
Patent number: 5965592Abstract: Compounds of the formula ##STR1## and their salts, in which R.sub.1, is a C.sub.1 -C.sub.7 aliphatic hydrocarbon radical; X.sub.1 is --CO; X.sub.2 is a divalent aliphatic hydrocarbon radical which comprises an ethyl group and an alkylene of 2 to 6 carbon atoms; R.sub.2 is hydroxy, carboxy or alkoxycarbonyl in which alkoxy is from 1 to 7 carbon atoms; X.sub.3 is a divalent aliphatic hydrocarbon; R.sub.3 is carboxyl or 5-tetrazolyl; and the rings A and B independently of one another are otherwise unsubstituted; can be prepared in a known manner and may be used as active ingredients for medicaments.Type: GrantFiled: July 29, 1998Date of Patent: October 12, 1999Assignee: Novartis CorporationInventors: Peter Buhlmayer, Franz Ostermayer, Tibur Schmidlin
-
Patent number: 5932758Abstract: Disclosed is a process for producing .beta.-amino-.alpha.-hydroxycarboxylic acid derivatives of general formula (2R,3S)- or (2S,3E)-N-(X,Y)-3-amino-2-hydroxy-3-phenyl propionic acid-Z of Formula I, ##STR1## e.g. of (2E,3S)-3-amino-2-hydroxy-3-phenyl propionic acid or (2R,3S)-N-benzoyl-3-amino-2-hydroxy-3-phenyl propionic acid methylester. Compounds of type I are valuable intermediates in the total synthesis of Taxols which can be used in the treatment of various forms of cancer.Type: GrantFiled: June 1, 1998Date of Patent: August 3, 1999Assignee: Degussa AktiengesellschaftInventors: Klaus Stingl, Matthias Kottenhahn, Karlheinz Drauz
-
Patent number: 5919786Abstract: The present invention relates to a compound of the formula (I): ##STR1## wherein Ar.sup.1, Ar.sup.2, Ar.sup.3 and Ar.sup.4 represent an aryl group or a heteroaromatic ring group; A represents a hydrocarbon group which may be substituted; X and Y represent an oxygen atom, a sulfur atom, a carbonyl group or a group of the formula --CHR.sup.a -- (wherein R.sup.a is a hydrogen atom or a lower alkyl group) or --NR.sup.b -- (wherein R.sup.b is a hydrogen atom or a lower alkyl group), or X and Y together represent a vinylene group or an ethynylene group; R.sup.1, R.sup.2, R.sup.3, R.sup.8 and R.sup.9 represent a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a lower alkoxy group; R.sup.4 and R.sup.Type: GrantFiled: March 25, 1998Date of Patent: July 6, 1999Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Yoshikazu Iwasawa, Tetsuya Aoyama, Kumiko Kawakami, Sachie Arai, Toshihiko Satoh, Yoshiaki Monden
-
Patent number: 5919790Abstract: The present invention relates to compounds that are inhibitors of interleukin-1.beta. converting enzyme that have the Formula II ##STR1## This invention also relates to a method of treatment of stroke, inflammatory diseases, septic shock, reperfusion injury, Alzheimer's disease, shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1.beta. converting enzyme.Type: GrantFiled: October 2, 1997Date of Patent: July 6, 1999Assignees: Warner-Lambert Company, BASF AktiengesellsschaftInventors: Hamish John Allen, Kenneth Dale Brady, Bradley William Caprathe, Paul Galatsis, John Lodge Gilmore, Sheryl Jeanne Hays, Robert Vincent Talanian, Nigel Walker, Joseph Scott Warmus
-
Patent number: 5907043Abstract: The present invention relates to pyrrolidine derivatives, and more particularly to the compound (S)-1-?(S)-2-(4-methoxybenzamido)-3-methylbutyryl!-N-?(S)-2-methyl-1-(trif luoroacetyl)propyl!pyrrolidine-2-carboxamide, shown by formula I, and solvates thereof. The present invention also provides pharmaceutical compositions, intermediates and methods of preparation of the compound. The compound of formula I is an inhibitor of human neutrophil elastase and is useful in the treatment of diseases in which the enzyme is implicated, such as, for example, emphysema and acute respiratory distress syndrome (ARDS).Type: GrantFiled: January 27, 1998Date of Patent: May 25, 1999Assignee: Zeneca LimitedInventors: Stephen John Pegg, George Joseph Sependa, Elwyn Peter Davies, Chris Allan Veale
-
Patent number: 5871755Abstract: The present invention relates to the use of dehydroalanine derivatives of formula (I) ##STR1## with R.sub.1 : H or linear- or branched-chain C.sub.1 C.sub.4 alkyl, ##STR2## or linear- or branched-chain C.sub.1 -C.sub.20 alkyl where X.sub.1, X.sub.2, X.sub.3, X.sub.4 and X.sub.5 =H, halogen, hydroxyl, linear-or branched-chain C.sub.1 -C.sub.4 alkyl or alkoxy, ##STR3## and n=2, 3 or 4, for protecting the skin, the mucous membranes and/or the hair against oxidative stress and to the cosmetic and dermatological compositions containing such compounds and to new dehydroalanine derivatives.Type: GrantFiled: September 15, 1995Date of Patent: February 16, 1999Assignee: L'OrealInventors: Sylvie Genard, Jean Baptiste Galey, Michel Hocquaux
-
Patent number: 5872280Abstract: The invention relates to benzoic acid derivatives being leukotriene antagonists. The compounds therefore are suitable as active ingredients in medicaments particularly in medicaments for the treatment of respiratory diseases.Type: GrantFiled: November 13, 1996Date of Patent: February 16, 1999Assignee: Bayer AktiengesellschaftInventors: Trevor Smyth Abram, Nigel James Cuthbert, Hilary Patricia Francis, Phillip John Gardiner, Peter Norman, Stephen Richard Tudhope
-
Patent number: 5866536Abstract: Carrier compounds, compositions, and dosage unit forms therefor which are useful in the delivery of active agents are provided. The present invention provides a compound having the formula: ##STR1## or a salt thereof, wherein the compound may be used in a composition or dosage unit form for delivery of at least one active agent, including a peptide, mucopolysaccharide, carbohydrate, or a lipid. Methods of administration and preparation of the compounds and compositions of the invention are provided as well, including oral administration. Further, the compositions of the invention may be prepared by mixing at least one active agent, at least one carrier compound, and, optionally, a dosing vehicle.Type: GrantFiled: February 6, 1997Date of Patent: February 2, 1999Assignee: Emisphere Technologies, Inc.Inventors: Andrea Leone-Bay, Koc-Kan Ho, Donald J. Sarubbi, Sam J. Milstein
-
Patent number: 5863947Abstract: A pharmaceutical compound of the formula: ##STR1## in which R.sup.1 is hydrogen, hydroxy or C.sub.1-6 alkoxy, R.sup.2 is hydrogen, carboxy, tetrazolyl, --SO.sub.2 H, --SO.sub.3 H, --OSO.sub.3 H, --CONHOH, or --P(OH)OR', --PO(OH)OR', --OP(OH)OR' or --OPO(OH)OR' where R' is hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl or aryl C.sub.1-6 alkyl,R.sup.3 is hydrogen, hydroxy or C.sub.1-4 alkoxy, andR.sup.4 is fluoro, trifluoromethyl, nitro, C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 alkylthio, heteroaryl, optionally substituted aryl, optionally substituted aryl C.sub.1-6 alkyl, optionally substituted aryl C.sub.2-6 alkenyl, optionally substituted aryl C.sub.2-6 alkynyl, optionally substituted aryloxy, optionally substituted aryl C.sub.1-6 alkoxy, optionally substituted arylthio, optionally substituted aryl C.sub.1-6 alkylthio or --CONR"R'", --SO.sub.2 NR"R"", --NR"R'", --OCONR"R"' or --SONR"R'" where R" and R'" are each hydrogen, C.sub.1-6 alkyl or aryl C.sub.Type: GrantFiled: May 9, 1997Date of Patent: January 26, 1999Assignee: Eli Lilly and Company LimitedInventors: Stephen Richard Baker, Barry Peter Clark, John Goldsworthy, John Richard Harris
-
Patent number: 5847194Abstract: Carbamoylcarboxamides of the general formula I ##STR1## and their salts (R.sup.1 is unsubstituted or substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl or an unsubstituted or substituted nonaromatic carbo- or heterocycle;R.sup.2 is H or unhalogenated or halogenated alkyl or cycloalkyl;R.sup.3 is unsubstituted or substituted alkyl, cycloalkyl or phenylalkyl;R.sup.4 is H or one of the radicals R.sup.3 orR.sup.3 and R.sup.4, together with the C atom to which they are bonded, are an unsubstituted or substituted carbo- or heterocycle;R.sup.5 independently of these is one of the radicals R.sup.2 ;X independently of one another is hydrogen, unsubstituted or substituted alkyl and/or alkenyl;Y independently of one another and of these is one of the radicals X;p,q independently of one another are 0, 1 or 2;R.sup.Type: GrantFiled: March 3, 1997Date of Patent: December 8, 1998Assignee: BASF AktiengesellschaftInventors: Frank Wetterich, Oliver Wagner, Karl Eicken, Eberhard Ammermann, Gisela Lorenz
-
Patent number: 5843997Abstract: The present invention provides novel compounds that affect excitatory amino acid receptors and are useful in the treatment of neurological disorders. This invention also provides synthetic methods for the preparation of the novel compounds.Type: GrantFiled: April 2, 1996Date of Patent: December 1, 1998Assignee: Eli Lilly and CompanyInventors: Lawrence J. Heinz, William H.W. Lunn, Darryle Darwin Schoepp
-
Patent number: 5840753Abstract: The present invention relates to the derivatives of formula: ##STR1## and to their use in therapeutics, especially as drugs with anti-inflammatory and analgesic properties.Type: GrantFiled: March 24, 1997Date of Patent: November 24, 1998Assignee: Laboratories UPSAInventors: Eric Nicolai, Jean-Marie Teulon
-
Patent number: 5837202Abstract: An fluorescent metal-chelating amphiphile having the structure: ##STR1## wherein A is a hydrophobic fluorophore, X and Y are aliphatic hydrocarbons having from 9 to 25 carbon atoms, B is a hydrophilic spacer, C is a metal chelator, and L is either an ether or ester linkage.The fluorescent metal-chelating amphiphile is combined with a matrix lipid to form lipid-based sensors which provide fluorometric detection of metal ions in liquids.Type: GrantFiled: September 11, 1996Date of Patent: November 17, 1998Assignee: California Institute of TechnologyInventors: Frances H. Arnold, Darryl Y. Sasaki
-
Patent number: 5811400Abstract: Compounds of the formula I ##STR1## as well as methods for their preparation, their pharmaceutical preparations and their use in therapy, especially as analgesics and as immunosuppressive agents.Type: GrantFiled: October 6, 1995Date of Patent: September 22, 1998Assignee: Astra ABInventor: Peter Schiller
-
Patent number: 5804552Abstract: Compounds wherein therapeutic peptides, including HIV protease inhibitors, are covalently linked to phospholipids, glycerides or other membrane-targeting and membrane-anchoring species, and their pharmaceutically acceptable salts, together with processes for their preparation. The invention also provides novel HIV protease inhibitors. The compounds of the present invention possess useful pharmacological properties such as antiviral activity towards viral infection and inhibitory activity towards viral proteases. Therefore, these compounds can be used in the prophylaxis or treatment of viral infections, in particular infections caused by HIV and other retroviruses. The targeting technology as described for the protease inhibitors is also applicable to a variety of inhibitors of other enzymes.Type: GrantFiled: June 2, 1995Date of Patent: September 8, 1998Assignee: NeXstar Pharmaceuticals, Inc.Inventors: Channa Basava, Karl Y. Hostetler
-
Patent number: 5804595Abstract: The invention provides certain amino acid conjugates of substituted 2-phenyl-N-?1-(phenyl)-2-(1-heterocycloalkyl- or heterocycloaryl-)ethyl!acetamides useful for selectively agonizing kappa opioid receptors in mammalian tissue.Type: GrantFiled: December 5, 1995Date of Patent: September 8, 1998Assignee: Regents of the University of MinnesotaInventors: Philip S. Portoghese, An-Chih Chang
-
Patent number: 5804581Abstract: Matrix metalloprotease inhibiting compounds, pharmaceutical compositions thereof and a method of disease treatment using such compounds are presented. The compounds of the invention have the generalized formula: ##STR1## wherein T is a substituent and R.sup.24 is a substituted amide moiety. These compounds are useful for inhibiting matrix metalloproteases and, therefore, combating conditions to which MMP's contribute, such as osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal disease, corneal ulceration, proteinuria, aneurysmal aortic disease, dystrophobic epidermolysis, bullosa, conditions leading to inflammatory responses, osteopenias mediated by MMP activity, tempera mandibular joint disease, demyelating diseases of the nervous system, tumor metastasis or degenerative cartilage loss following traumatic joint injury, and coronary thrombosis from athrosclerotic plaque rupture. The present invention also provides pharmaceutical compositions and methods for treating such conditions.Type: GrantFiled: May 15, 1997Date of Patent: September 8, 1998Assignee: Bayer CorporationInventor: Donald J. Wolanin
-
Patent number: 5804688Abstract: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.Type: GrantFiled: February 7, 1997Date of Patent: September 8, 1998Assignee: Emisphere Technologies, Inc.Inventors: Andrea Leone-Bay, Eric Wang, Donald J. Sarubbi, Harry Leipold
-
Patent number: 5786508Abstract: The present invention relates to the use in the treatment of cognitive disorders associated with the aging processes of the brain and perinatal brain disorders of compounds which act as inhibitors of the enzyme kynurenine aminotransferase (KAT).The present invention also provides, as novel compounds, a selected class of KAT inhibitors which are the compounds of formula (IA) ##STR1## wherein R is halogen, C.sub.1 -C.sub.6 alkyl, C.sub.5 -C.sub.7 cycloalkyl, phenyl-C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.6 -C.sub.10 aryloxy, phenyl-C.sub.1 -C.sub.4 alkoxy or trifluoromethyl, andR.sub.1 is hydroxy, C.sub.1 -C.sub.6 alkoxy, amino, mono-C.sub.1 -C.sub.6 alkylamino, di-C.sub.1 -C.sub.6 alkylamino, hydroxylamino, C.sub.1 -C.sub.4 alkoxyamino or benzyloxyamino,with the provisos that:(i) when R.sub.1 is hydroxy and, at the same time, R is halogen, then this halogen is not fluorine; and(ii) when R.sub.1 is hydroxy and, at the same time, R is C.sub.1 -C.sub.6 alkyl, then this C.sub.1 -C.sub.Type: GrantFiled: April 6, 1995Date of Patent: July 28, 1998Assignees: Pharmacia & Upjohn S.p.A., University of Maryland at BaltimoreInventors: Robert Schwarcz, Mario Varasi, Arturo Della Torre, Carmela Speciale, Alberto Bianchetti
-
Patent number: 5773284Abstract: Process for the preparation of a threo-phenylserine amide of the general formula 2 in which glycine amide is contacted with the corresponding substituted benzaldehyde of formula 3 in an excess relative to the amount of glycine amide, this taking place at a pH between 9 and 14 in the presence of a suitable solvent. The resulting phenylserine amide can subsequently be hydrolyzed to a phenylserine amide of the general formula 1, which is subsequently hydrolyzed to a phenylserine amide of the general formula 1, which is subsequently subjected to a stereoselective enzymatic hydrolysis yielding a (2S,3R) phenylserine. The non-hydrolyzed (2R,3S) phenylserine amide can be isolated as a Schiff base and be recirculated and simply racemized. The (2S,3R) phenylserine obtained can be used in the preparation of thiamphenicol or florfenicol. The threo-phenylserine amides of the general formula 1 or 2 are new intermediates in this commercially attractive process for the preparation of thiamphenicol and florfenicol.Type: GrantFiled: June 12, 1996Date of Patent: June 30, 1998Assignee: DSM N.V.Inventor: Bernardus Kaptein
-
Patent number: 5773647Abstract: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.Type: GrantFiled: February 7, 1997Date of Patent: June 30, 1998Assignee: Emisphere Technologies, Inc.Inventors: Andrea Leone-Bay, Eric Wang, Donald J. Sarubbi, Harry Leipold
-
Patent number: 5739387Abstract: Racemic or optically active threo-3-(3,4-dihydroxyphenyl)serine can be readily produced via a few short steps by a process involving the steps of reacting a racemic or optically active N-acyl DOPA derivative represented by the formula ?I!: ##STR1## wherein X is a halogen atom; n is 0, 1, 2 or 3; R.sup.1 and R.sup.2 independently represent a protecting group for a hydroxyl group; R.sup.3 is a protecting group for carboxyl group; R.sup.4 is an alkyl group which may have a substituent or a phenyl group which may have a substituent; and a carbon marked with the symbol * is an asymmetric carbon, with a halogen radical generator, a cerium (IV) salt, or a persulfate salt in the presence of a copper catalyst to produce racemic or optically active oxazolines represented by the formula ?IV!: ##STR2## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X, n and * are as defined above; and thereafter conducting an oxazoline ring opening and removing R.sup.1, R.sup.2 and R.sup.3 and, optionally, removing X when n is 1, 2 or 3.Type: GrantFiled: May 20, 1996Date of Patent: April 14, 1998Assignee: Sumitomo Chemical Company, LimitedInventors: Yoshiaki Oda, Kazunori Iwakura
-
Patent number: 5719306Abstract: The present invention provides compounds of the formula Ar.sup.1 --Q--Ar.sup.2 --Y--R--Z and pharmaceutically acceptable salts thereof wherein Ar.sup.1 and Ar.sup.2 are optionally substituted aryl moieties, Z is an optionally substituted nitrogen-containing moiety which may be an acyclic, cyclic or bicyclic amine or an optionally substituted monocyclic or bicyclic nitrogen-containing heteroaromatic moiety; Q is a linking group capable of linking two aryl groups; R is an alkylene moiety; Y is a linking moiety capable of linking an aryl group to an alkylene moiety and wherein Z is bonded to R through a nitrogen atom. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of inflammatory diseases which are mediated by LTB.sub.4 production, such as psoriasis, ulcerative colitis, IBD and asthma.Type: GrantFiled: June 6, 1995Date of Patent: February 17, 1998Assignee: G.D. Searle & Co.Inventors: Nizal Samuel Chandrakumar, Barbara Baosheng Chen, Michael Clare, Bipinchandra Nanubhai Desai, Stevan Wakefield Djuric, Stephen Hermann Docter, Alan Frank Gasiecki, Richard Arthur Haack, Chi-Dean Liang, Julie Marion Miyashiro, Thomas Dale Penning, Mark Andrew Russell, Stella Siu-tzyy Yu
-
Patent number: 5717109Abstract: The present invention provides compounds of formula ##STR1## in which R represents an organic group, or a pharmaceutically acceptable metabolically labile ester or amide thereof, or a pharmaceutically acceptable salt thereof, which are useful as antagonists of one or more of the actions of L-glutamate at metabotropic excitatory amino acid receptors.Type: GrantFiled: July 10, 1995Date of Patent: February 10, 1998Assignee: Eli Lilly and CompanyInventors: M. Brian Arnold, Thomas J. Bleisch, David R. Helton, Mary Jeanne Kallman, Paul L. Ornstein, Darryle D. Schoepp, Joseph P. Tizzano
-
Patent number: 5714631Abstract: A group of functionalized amine chelants having ortho ligating functionality that form complexes with rare-earth type metal ions are disclosed. The complexes can be covalently attached to an antibody or antibody fragment and used for therapeutic and/or diagnostic purposes. In addition certain of the chelant-radionuclide complexes can be effectively employed in compositions useful as therapeutic and/or diagnostic agents for calcific tumors and/or relief of bone pain.Type: GrantFiled: February 6, 1996Date of Patent: February 3, 1998Assignee: The Dow Chemical CompanyInventors: David A. Wilson, Joseph R. Garlich, R. Keith Frank, Kenneth McMillan, Jaime Simon
-
Patent number: 5712266Abstract: A syn isomer in (R) or (S) form or a mixture thereof of a compound of the formula ##STR1## syn isomer, in the (R) or (S) form or in the form of an (R,S) mixture, in the form of an internal salt or their salts with organic or mineral acids wherein the substituents are defined as in the application having anti-bacterial properties.Type: GrantFiled: May 30, 1995Date of Patent: January 27, 1998Assignee: Roussel UclafInventors: Jozsef Aszodi, Jean-Francois Chantot, Patrick Fauveau, Solange Gouin D'Ambrieres, Daniel Humbert, Christophe Dini
-
Patent number: 5703095Abstract: N-arylmethylene ethylenediaminetriacetate, N-arylmethylene iminodiacetate or N,N'-diarylmethylene ethylenediaminediacetate type compounds and their use in combatting oxidative stress, and pharmaceutical and cosmetic compositions comprising said compounds. The invention also concerns a process for the preparation of said compounds.Type: GrantFiled: June 27, 1995Date of Patent: December 30, 1997Assignee: L'OrealInventors: Jean Baptiste Galey, Jacqueline Dumats